CorMedix Announces SPA Agreement With FDA For Phase 3 Trial in the Prevention of Contrast-Induced Acute Kidney Injury Study With CRMD001 (A Proprietary Formulation of Deferiprone)

BRIDGEWATER, N.J.--(BUSINESS WIRE)--CorMedix Inc. (“CorMedix”) (NYSE Amex: CRMD), a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it has received a Special Protocol – Agreement letter from the U.S. Food and Drug Administration (“FDA”) regarding a Special Protocol Assessment (“SPA”) on the design of a pivotal Phase 3 trial for the Company’s oral formulation of CRMD001 in the prevention of Contrast-Induced Acute Kidney Injury (“CI-AKI”). This SPA takes into consideration a modification to the dosing regimen contained in the previously submitted protocol.
MORE ON THIS TOPIC